Bronchitis - A Pipeline Analysis Report by Technavio
LONDON--(BUSINESS WIRE)--May 14, 2018-- has announced their latest pipeline analysis report on the market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat bronchitis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180514005731/en/
Technavio has published a new pipeline analysis report on the global bronchitis market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
Bronchitis - market overview
is an unusual inflammation of the air passages between the nose and the lungs. Under such conditions, the bronchial tubes become narrow, and they start secreting thick mucus, which is often pale and discolored. Bronchitis is a result of a common cough and cold, which lasts for more than a week. Bronchitis can be either acute or chronic.
According to a senior analyst at Technavio for , “Acute bronchitis, also called chest cold, is a condition where a cough usually endures around 2-3 weeks. Acute bronchitis has the high probability of developing pneumonia in children, however, it does not require any treatment and can be cured on its own.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
This market research report segments the market based on therapies employed that includes monotherapy and undisclosed, RoA (oral, subcutaneous, and undefined), therapeutic modalities (monoclonal antibody, small molecules, vaccine, and undisclosed), targets for drugs under development (23S rRNA of 50S ribosomal subunit, IgE, type II and IV topoisomerases, and undisclosed), drugs under development (discovery, phase II, phase II/III, phase III, and NDA), and recruitment status (not yet recruiting, recruiting, active not recruiting, and undisclosed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180514005731/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY HEALTH GENETICS INFECTIOUS DISEASES RESEARCH OTHER SCIENCE SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/14/2018 09:32 AM/DISC: 05/14/2018 09:32 AM